pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated patent portfolio — 8292 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Regeneron Ireland Designated patents
8,292 pharmaceutical patents indexed for Regeneron Ireland Designated. 419 expire within 24 months.
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 419 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11208330
Identification and optimization of carbon radicals on hydrated graphene oxide for ubiquitous antibacterial coatings
granted -
US 11208634
Deimmunized therapeutic compositions and methods
granted -
US 11202801
Notch receptors with hinge domain
granted -
US 11202808
Methods for treating autism spectrum disorder and associated symptoms
granted -
US 11203618
Campylobacter immunogenic compositions and uses thereof
granted -
US 11203582
Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress
granted -
US 11203583
Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting
granted -
US 11203754
Microrna compositions and methods of making and using same
granted -
US 11198724
Treatment of staphylococcal disorders
granted -
US 11197932
Polymer-drug conjugates for combination anticancer therapy
granted -
US 11198682
Substituted pyrimidines as inhibitors for a Rho family of GTP-ases
granted -
US 11197822
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 11197812
Cosmetic formulations for topical applications containing erythropoietin-derived molecules
granted -
US 11197876
Effects of LGM2605 on a primate model of asthma
granted -
US 11197844
Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
granted -
US 11202152
Acoustic beamforming
granted -
US 11198694
HDAC6 inhibitors, with improved solubility and their uses
granted -
US 11197883
Inhibition of stress granule formation through manipulation of UBAP2L
granted -
US 11197928
Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
granted -
US 11191855
1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof
granted -
US 11192898
MDM2 protein degraders
granted -
US 11192869
CFTR regulators and methods of use thereof
granted -
US 11191778
Multifunctional linker technology containing an N4 group
granted -
US 11191750
Use of mTOR inhibitors for treatment of familial adenomatous polyposis
granted -
US 11191774
Drug formulations for cancer treatment
granted -
US 11192978
Reversibly crosslinked micelle systems
granted -
US 11192958
Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
granted -
US 11185499
Multilayer thin film drug delivery device and methods of making and using the same
granted -
US 11185601
Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
granted -
US 11185498
Multilayer thin film drug delivery device and methods of making and using the same
granted -
US 11186849
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11186611
Peptide with anti-obesity and anti-diabetes activity and use thereof
granted -
US 11185577
H3.3 CTL peptides and uses thereof
granted -
US 11185580
Compositions, methods and uses for improved human papilloma virus constructs
granted -
US 11185554
Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease
granted -
US 11185585
Methods and compositions for improving antiangiogenic therapy with anti-integrins
granted -
US 11181536
Methods for monitoring treatment of chronic liver disease
granted -
US 11180498
Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals
granted -
US 11180499
Phosphodiesterase inhibitors
granted -
US 11181520
Systems and methods for high-resolution imaging
granted -
US 11179439
Methods and compositions for preventing and treating damage to the heart
granted -
US 11179435
Hangover alleviating composition containing conjugate of sesamol and peptide as active ingredient
granted -
US 11180452
Methods and compositions for selectively inhibiting pathogenic microbes
granted -
US 11180765
Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety
granted -
US 11180492
Anti-parasitic compounds and uses thereof
granted -
US 11173291
Implantable drug delivery devices for localized drug delivery
granted -
US 11173227
Wound dressings and applications thereof
granted -
US 11173235
Nitrite eluting devices and methods of use thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
419 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.